嵌合抗原受体
过继性细胞移植
免疫学
细胞毒性T细胞
细胞疗法
生物
免疫疗法
抗原
免疫系统
临床试验
T细胞
细胞
生物信息学
体外
遗传学
作者
Zachary Walsh,Yinmeng Yang,M. Eric Kohler
摘要
Abstract Advances in the development of immunotherapies have offered exciting new options for the treatment of malignant diseases that are refractory to conventional cytotoxic chemotherapies. The adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has demonstrated dramatic results in clinical trials and highlights the promise of novel immune‐based approaches to the treatment of cancer. As experience with CAR T cells has expanded with longer follow‐up and to a broader range of diseases, new obstacles have been identified which limit the potential lifelong benefits of CAR T cell therapy. These obstacles highlight not only the gaps in knowledge of the optimal clinical application of this “living drug”, but also gaps in our understanding of the fundamental biology of CAR T cells themselves. In this review, we discuss the obstacles facing CAR T cell therapy, how these relate to our current understanding of CAR T cell biology and approaches to enhance the clinical efficacy of this therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI